MX2023001232A - Medicamentos antiplaquetarios y usos de estos. - Google Patents
Medicamentos antiplaquetarios y usos de estos.Info
- Publication number
- MX2023001232A MX2023001232A MX2023001232A MX2023001232A MX2023001232A MX 2023001232 A MX2023001232 A MX 2023001232A MX 2023001232 A MX2023001232 A MX 2023001232A MX 2023001232 A MX2023001232 A MX 2023001232A MX 2023001232 A MX2023001232 A MX 2023001232A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- antiplatelet drugs
- pharmaceutical compositions
- administering
- present disclosure
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
La presente divulgación se refiere a compuestos que exhiben actividad en la inhibición de la agregación plaquetaria, así como a composiciones farmacéuticas que comprenden estos compuestos y métodos de tratamiento de enfermedades vasculares mediante la administración de estos compuestos o las composiciones farmacéuticas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2020105513 | 2020-07-29 | ||
| PCT/CN2021/108875 WO2022022559A1 (en) | 2020-07-29 | 2021-07-28 | Antiplatelet drugs and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023001232A true MX2023001232A (es) | 2023-05-15 |
Family
ID=80037185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023001232A MX2023001232A (es) | 2020-07-29 | 2021-07-28 | Medicamentos antiplaquetarios y usos de estos. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240279178A1 (es) |
| EP (2) | EP4188935A4 (es) |
| JP (1) | JP2023535815A (es) |
| KR (2) | KR20230047425A (es) |
| CN (4) | CN119033782B (es) |
| AR (1) | AR123078A1 (es) |
| AU (1) | AU2021317436A1 (es) |
| BR (1) | BR112023001595A2 (es) |
| CA (1) | CA3186645A1 (es) |
| IL (1) | IL299979A (es) |
| MX (1) | MX2023001232A (es) |
| TW (1) | TW202214609A (es) |
| WO (1) | WO2022022559A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202339745A (zh) * | 2022-01-28 | 2023-10-16 | 大陸商上海柯君醫藥科技有限公司 | 抗血小板藥物的藥物組合物及其用途 |
| CN116813532A (zh) * | 2023-06-29 | 2023-09-29 | 上海柯君医药科技有限公司 | 一种哌啶化合物的制备方法 |
| WO2025108300A1 (zh) * | 2023-11-24 | 2025-05-30 | 上海柯君医药科技有限公司 | 一种含哌啶环化合物的苯磺酸盐的晶型、其制备方法及应用 |
| WO2025108307A1 (zh) * | 2023-11-24 | 2025-05-30 | 上海柯君医药科技有限公司 | 一种含哌啶环化合物的苯磺酸盐、其制备方法及应用 |
| CN119019320B (zh) * | 2024-10-29 | 2025-03-11 | 上海柯君医药科技有限公司 | 一种具有抗血小板活性的哌啶类化合物的制备方法 |
| CN119176829B (zh) * | 2024-11-26 | 2025-04-15 | 上海柯君医药科技有限公司 | 一种哌啶环化合物的制备方法 |
| CN119192061B (zh) * | 2024-11-28 | 2025-05-13 | 上海柯君医药科技有限公司 | 一种含哌啶环的化合物的纯化方法 |
| CN119371453A (zh) * | 2024-12-30 | 2025-01-28 | 上海柯君医药科技有限公司 | 一种抗血小板药物中间体的制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ334389A (en) * | 1996-08-28 | 2001-05-25 | Ube Industries | Cyclic amine derivatives |
| EP1773370A1 (en) * | 2004-07-07 | 2007-04-18 | Medicure International Inc. | Combination therapies employing platelet aggregation drugs |
| CN103626694A (zh) * | 2012-08-29 | 2014-03-12 | 中国药科大学 | 不饱和环胺衍生物、其制备方法及其医药用途 |
| CN106554368A (zh) * | 2015-09-25 | 2017-04-05 | 陕西合成药业股份有限公司 | 噻吩并吡啶类衍生物及其制备方法和用途 |
| CN106554303A (zh) * | 2015-09-25 | 2017-04-05 | 陕西合成药业股份有限公司 | 噻吩并吡啶类衍生物及其制备方法和用途 |
-
2021
- 2021-07-28 MX MX2023001232A patent/MX2023001232A/es unknown
- 2021-07-28 CA CA3186645A patent/CA3186645A1/en active Pending
- 2021-07-28 CN CN202410873004.4A patent/CN119033782B/zh active Active
- 2021-07-28 IL IL299979A patent/IL299979A/en unknown
- 2021-07-28 BR BR112023001595A patent/BR112023001595A2/pt unknown
- 2021-07-28 AU AU2021317436A patent/AU2021317436A1/en active Pending
- 2021-07-28 JP JP2023506150A patent/JP2023535815A/ja active Pending
- 2021-07-28 CN CN202311275197.5A patent/CN117343000A/zh active Pending
- 2021-07-28 CN CN202180058245.8A patent/CN116194459A/zh active Pending
- 2021-07-28 KR KR1020237007048A patent/KR20230047425A/ko active Pending
- 2021-07-28 CN CN202411716601.2A patent/CN119552111A/zh active Pending
- 2021-07-28 EP EP21851193.9A patent/EP4188935A4/en active Pending
- 2021-07-28 KR KR1020257016343A patent/KR20250073569A/ko active Pending
- 2021-07-28 EP EP24156405.3A patent/EP4342532A3/en active Pending
- 2021-07-28 US US18/018,576 patent/US20240279178A1/en active Pending
- 2021-07-28 WO PCT/CN2021/108875 patent/WO2022022559A1/en active Application Filing
- 2021-07-29 AR ARP210102107A patent/AR123078A1/es unknown
- 2021-07-29 TW TW110127818A patent/TW202214609A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20240279178A1 (en) | 2024-08-22 |
| TW202214609A (zh) | 2022-04-16 |
| IL299979A (en) | 2023-03-01 |
| CN116194459A (zh) | 2023-05-30 |
| CN119033782A (zh) | 2024-11-29 |
| EP4342532A2 (en) | 2024-03-27 |
| BR112023001595A2 (pt) | 2023-04-04 |
| CN119552111A (zh) | 2025-03-04 |
| KR20230047425A (ko) | 2023-04-07 |
| CA3186645A1 (en) | 2022-02-03 |
| AU2021317436A1 (en) | 2023-02-23 |
| EP4342532A3 (en) | 2024-07-17 |
| WO2022022559A1 (en) | 2022-02-03 |
| EP4188935A1 (en) | 2023-06-07 |
| CN119033782B (zh) | 2025-04-25 |
| KR20250073569A (ko) | 2025-05-27 |
| EP4188935A4 (en) | 2024-07-17 |
| AR123078A1 (es) | 2022-10-26 |
| JP2023535815A (ja) | 2023-08-21 |
| CN117343000A (zh) | 2024-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023001232A (es) | Medicamentos antiplaquetarios y usos de estos. | |
| CO2022018811A2 (es) | Inhibidores de la proteína kras g12c y usos de estos | |
| BR112017003302A2 (pt) | sal de adição de ácido do composto inibidor de trk | |
| MX2021007468A (es) | Compuestos que participan en la union cooperativa y usos de los mismos. | |
| EA201990665A1 (ru) | Регуляторы hpk1 на основе производных пиразолопиридина и их применение для лечения рака | |
| BR112015028879A8 (pt) | compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos | |
| BR112019024264A2 (pt) | Antimitoscinas: inibidores direcionados da biogênese mitoconcrial para erradicação de células-tronco de câncer | |
| CO2019007409A2 (es) | Derivados de la pirimidin enona tricíclica para la inhibición de rorγ y otros usos | |
| BR112019008431A2 (pt) | aplicação de (s)-norcetamina e sal da mesma como fármaco | |
| BR112018071408A2 (pt) | “composto inibidor de rip2 quinase, composição farmacêutica, usos de um composto e de uma combinação, e, combinação | |
| BR112013018920A2 (pt) | composições de nanopartículas, formulações destas e seus usos | |
| MX376306B (es) | Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de cinasa pim. | |
| MX2018003569A (es) | Derivados de acido oleanolico modificado en c4 para la inhibicion de il-17 y otros usos. | |
| DOP2017000191A (es) | Nuevas proteínas específicas para pioverdina y pioquelina | |
| BR112017003433A2 (pt) | inibidores espirocíclicos de catepsina c | |
| DOP2016000253A (es) | Nuevos compuestos | |
| MX2022014925A (es) | Moduladores de il-17a. | |
| BR112015019412A8 (pt) | inibidores de bace1, seus usos, e composição farmacêutica | |
| BR112015018491A2 (pt) | triterpenoides c-19-modificados com atividade inibidora de maturação de hiv | |
| MX2022014924A (es) | Moduladores de il-17a. | |
| ECSP15000868A (es) | Derivados de estra1,3,5(10),16tetraeno 3sustituidos, métodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos | |
| EA201691570A1 (ru) | Фармацевтическая композиция, включающая диамино-гетероциклическое карбоксамидное соединение в качестве активного ингредиента | |
| MX384072B (es) | Compuesto derivado de pirrolo-piridina, metodo para preparar el mismo y composicion farmaceutica que contiene el mismo como ingrediente activo para la prevencion o el tratamiento de enfermedades relacionadas con la proteina cinasa. | |
| BR112017024727A2 (pt) | cocristal, composição farmacêutica, método de tratamento de uma doença em um indivíduo e processo de produção de um cocristal | |
| CO2023000858A2 (es) | Inhibidores de atr y usos de estos |